GLP-1 agonist drugs (such as semaglutide and tirzepatid), which have become popular in recent years and are known among the public as "weight loss pens," are now coming to the forefront in cancer research, moving beyond their proven benefits in the treatment of obesity and type 2 diabetes. New scientific studies have provided exciting findings suggesting that these drugs could reduce the risk of disease progression, especially in specific types of cancer such as breast, bowel, lung, and liver. Obesity has long been considered a known and accepted major risk factor for various types of cancer. Previously, it had been observed that interventions such as bariatric surgery applied to obese patients created positive effects in preventing cancer by causing weight loss. Whether similar positive mechanisms can be seen with these new-generation weight loss drugs has become a critical research topic closely examined by scientists today.
These drug groups, known as GLP-1 agonists, work as mimics of a natural hormone produced in the intestines that regulates both glucose control and appetite. By balancing patients' blood sugar and severely suppressing appetite, these drugs not only support an effective weight loss process but also improve the body's overall metabolic environment. Experts noting that cancer is fundamentally considered a metabolic disease act on the biological logic that reducing chronic inflammation associated with obesity could slow down tumor development. As the volume of fat tissue in the body decreases with the use of these drugs, the production of harmful chemicals that pave the way for tumor growth is also thought to slow down. Therefore, the potential effects of these drugs, which are not limited to just obesity or diabetes, in the field of oncology are being investigated with increasing curiosity in the scientific world.
One of the most striking findings in this field was obtained in a comprehensive study that analyzed data from more than 1.6 million type 2 diabetes patients. The study in question revealed that patients using GLP-1 agonists had a significantly lower likelihood of developing some of the 13 different types of cancer directly linked to obesity. One of the most recent and noteworthy studies on this topic was presented to the attention of scientists at the annual congress of the American Society of Clinical Oncology (ASCO). The aforementioned comprehensive research deeply analyzed the data of more than 12 thousand patients who had already been diagnosed with cancer and whose disease was still at an early or regional stage. Researchers examined the risks of metastasis (spread) during the treatment process in detail by comparing this large patient group with different types of cancer according to the types of drugs used.
The study presented at the ASCO congress focused on seven different types of cancer closely related to obesity, such as breast, prostate, lung, colorectal, liver, kidney, and pancreatic cancers. According to the research data, it was determined that the risk of cancer patients using these drugs progressing to the advanced metastatic stage in four different types of the disease decreased significantly. For example, the rate of lung cancer becoming metastatic in those using these drugs is 10 percent, while in the control group using other diabetes drugs, this rate goes up to 22 percent. Similarly, in breast cancer, these rates showed a significant difference of 10 percent versus 20 percent, and in colorectal cancer, 13 percent versus 22 percent. In liver tumors, the spread rate was recorded as 19 percent versus 28 percent, which means a dramatic decrease between 38 percent and 50 percent in the overall risk of disease progression.
Despite this data, scientists refrain from explicitly stating whether the observed benefits directly result from a strong effect of the drugs on tumors. It is highly likely that this positive development in disease progression is a consequence of indirect factors such as the significant weight loss patients experience, the reduction of inflammation in the body, and the overall improvement of metabolism. It is known that fat tissue is not merely an energy store in the body but also an active organ that produces biological signals and substances that can trigger tumor mechanisms. For this reason, the fat loss provided by these drugs is thought to create an ecological effect at the cellular level that complicates cancer development, going far beyond the decrease in body weight. All these relevant findings once again demonstrate how crucial the fight against obesity is in cancer treatment and prevention processes.
이 기사에 대해 질문
답변은 이 기사만을 바탕으로 AI가 생성합니다.